Xiaflex® (collagenase clostridium histolyticum)

Xiaflex is covered for adults (≥18) with FDA‑approved Dupuytren's contracture (palpable cord with MP or PIP contracture ≥20°) and Peyronie's disease (palpable plaque with curvature ≥30°, or ≥15° if previously treated with Xiaflex) and is excluded for patients who are under 18, who do not meet the baseline deformity thresholds, or who have already received a complete 8‑injection course for Peyronie's. Coverage requires documentation of baseline measurements and prior treatment, administration by a provider experienced in the relevant condition, and adherence to dosing/frequency limits (0.58 mg per injection; Dupuytren's max 3 injections per cord, ≤2 cords per visit, ≥4 weeks between injections; Peyronie's max 4 cycles of 2 injections [8 total], second injection 1–3 days after the first and ~6 weeks between cycles).

"Xiaflex is indicated for the treatment of adult patients with Dupuytren's contracture with palpable cord."